Hello and welcome to the details of Sinopharm's Wuhan affiliate boosts Covid-19 shot annual capacity to one billion doses and now with the details
Follow us on Instagram and subscribe to our Telegram channel for the latest updates on news you need to know.
BEIJING, June 1 ― A Wuhan-based affiliate of China National Pharmaceutical Group (Sinopharm) said the start of operations at a new factory will raise the annual production capacity of its Covid-19 vaccine to at least 1 billion doses.
The Wuhan Institute of Biological Products made the announcement in a statement released late on Monday through social media. It did not specify when it will operate the factory at full capacity.
Still, the announcement marks a step toward state-backed Sinopharm's annual capacity target of 3 billion doses for its Covid-19 vaccines.
The Beijing Institute of Biological Products, another Sinopharm affiliate whose shot gained emergency-use approval from the World Health Organisation, has a factory with annual capacity of 1 billion doses and is also building a new facility.
China has approved four Covid-19 vaccines from domestic makers Sinopharm, Sinovac Biotech Ltd and CanSino Biologics Inc for general public use, and three other vaccines for emergency use.
Sinovac, whose Covid-19 vaccine capacity is 2 billion doses per year, today said it has supplied over 600 million doses at home and abroad as of the end of May. ― Reuters
These were the details of the news Sinopharm's Wuhan affiliate boosts Covid-19 shot annual capacity to one billion doses for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.